Several types of tumors (basal cell carcinomas, gliomas, medullablastomas, and prostate cancer) express abnormally high levels of GLI proteins or increased SHH pathway activation, which may be targets for therapy [42]. This evidence concerns the gene SHH and basal cell carcinoma.